Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.
|Articles|March 24, 2022
Disability Insurance: Overview, What to Look For, Mistakes to Avoid
Advertisement
One could argue that disability income insurance is the most vital of coverages that we will purchase over our working career but because disability insurance is one of the most complex financial and insurance tools, we are often left with many unanswered questions.
This eBook was put together to be a resource for those unanswered questions. Gain insight into disability insurance with an overview of what to look for and what mistakes to avoid when purchasing this vital protection for you and your family's future.
Fill out the form below to download the eBook:
Sponsored by:
Advertisement
Related to this article
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]
All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
2
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
3
TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome
4
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
5